Mednet Logo
HomeEndocrinology
Endocrinology

Endocrinology

Physician discussions on diabetes management, thyroid disorders, hormonal imbalances, and metabolic conditions.

Recent Discussions

What role does external beam radiotherapy play in the treatment of well differentiated papillary thyroid cancer when a total thyroidectomy and lymph node dissection cannot be performed?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · West Virginia University

Following a partial thyroidectomy (meaning less than a near-total extirpation and gross residual disease), the role of RAI is unproven and the likelihood of morbidity is real. In terms of XRT, and in a patient with reasonable co-morbidities, I would offer XRT to 60-66 Gy. Keep an eye on spinal cord ...

When is the best time to start denosumab in men with metastatic prostate cancer?

3
2 Answers

Mednet Member
Mednet Member
Medical Oncology · Cedars-Sinai Medical Center

The data supporting the use of bone modifying agents (BMAs) such as denosumab or zoledronic acid are certainly the most solid for men with castration-resistant prostate cancer (i.e. progresion of disease through inital LHRH analog therapy) (Saad, JNCI 2004; 94: 1458–68; Fizzazi Lancet Oncol 2011; 37...

Should bone-directed agents, such as denosumab or zoledronic acid, be given when patients are being treated with radium-223?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Montefiore Medcal Center

In ALSYMPCA, bisphosphonate use at study entry was associated with a delay in symptomatic skeletal events (Sartor, et al. Lancet Oncol 2014; 15(7) 738-46). Based on this, osteoclast-targeted agents (i.e. zoledronic acid and denosumab) should be offered to patients with mCRPC that will receive radium...

Based on the recent disease-free survival results from ABCSG-18 presented at San Antonio, do you favor the use of Denosumab in the adjuvant setting?

1
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Indiana University School of Medicine

I'll give you the simple answer first - YES. In those receiving AI adjuvant therapy (whether postmenopasual or pre with ovarian suppression/ablation). We've struggled with how (and whether) to use bisphosphonates in the adjuvant setting. The meta-analysis found a significant improvement of similar m...

How would you follow patients with differentiated thyroid cancer that no longer picks up iodine after thyroidectomy and RAI, and have thyroglobulin antibodies?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · West Virginia University

The presence of antibodies makes measuring the thyroglobulin level essentailly inaccurate. PET imaging may have a role though clear data on its utlity is limited (and it's expensive). Physical exams and Ultrasonography is the best way of monitoring the disease state from a surveillance point. For sy...

How common is hypothyroidism in postradiation head and neck cancer patients?

2
3 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Texas MD Anderson Cancer Center

The incidence of postradiation hypothyroidism is hard to determine, as the literature is quite varied. This variation is due to a combination of how hypothyroidism is measured, how much of the thyroid was treated, and when patients were assessed. Recent literature suggests the incidence can approxim...

When treating patients with immune checkpoint inhibitors, do you routinely check markers of endocrinopathies such as TSH/ACTH, or only when a patient has symptoms?

3
1 Answers

Mednet Member
Mednet Member
Medical Oncology · The Ohio State University School of Medicine

There are clearly defined parameters for routine monitoring that are outlined in the NCCN guidelines. We have incorporated these into our treatment plans. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf

What is your approach to the use of denosumab in patients with metastatic breast cancer with bony involvement?

2
1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Texas MD Anderson Cancer Center

I do not extrapolate the results of OPTIMIZE-2 and CALGB 70604 to denosumab. It is a different drug and until appropriate studies are performed, there is no reason to change its dose or schedule.

Is it safe to use radioactive iodine therapy for patients with differentiated thyroid cancer and brain metastases?

3 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Louisville School of Medicine

Not all brain metastases from thyroid cancer accumulate radioactive iodine. It is not unsafe to use radioactive iodine in the presence of brain metastases, whether they have been treated with whole brain RT or SRS/SRT. If the brain metastases pick up radioactive iodine, there could be increased peri...

How long after the presentation of Graves ophthalmopathy is orbital radiotherapy helpful?

2
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

Radiation dose helps with graves disease. In the past, we have used 20 Gy in 10 fraction, but there are recent reports of using very low doses as anti inflammatory, like .2 Gy to 1 to 2 Gy total dose with good efficacy and limited or no side effects.